Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Common Equity (2016 - 2025)

Historic Common Equity for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $950.2 million.

  • Ligand Pharmaceuticals' Common Equity rose 1295.72% to $950.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $950.2 million, marking a year-over-year increase of 1295.72%. This contributed to the annual value of $830.4 million for FY2024, which is 1847.96% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Common Equity of $950.2 million as of Q3 2025, which was up 1295.72% from $828.5 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Common Equity ranged from a high of $950.2 million in Q3 2025 and a low of $597.5 million during Q4 2022
  • Its 5-year average for Common Equity is $772.8 million, with a median of $795.5 million in 2025.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Common Equity plummeted by 2723.88% in 2022 and then surged by 2594.45% in 2024.
  • Ligand Pharmaceuticals' Common Equity (Quarter) stood at $821.2 million in 2021, then decreased by 27.24% to $597.5 million in 2022, then increased by 17.31% to $700.9 million in 2023, then grew by 18.48% to $830.4 million in 2024, then grew by 14.42% to $950.2 million in 2025.
  • Its Common Equity was $950.2 million in Q3 2025, compared to $828.5 million in Q2 2025 and $795.5 million in Q1 2025.